Stocky turns companies like NEWRON PHARMACEUTICALS SPA NEWR into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. 0QOI.L scores 34/100 overall, held back by a weak Value Compounder Score (20/100) indicating limited earnings power or capital efficiency, and moderate Leadership Alignment (45/100) suggesting misaligned incentives. Vulnerability Profile is adequate but offers no margin of safety—financial buffer alone cannot offset the lack of durable competitive advantage or earnings momentum.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for NEWRON PHARMACEUTICALS SPA NEWR:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 34/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates NEWRON PHARMACEUTICALS SPA NEWR (0QOI.L) at 34/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. 0QOI.L scores 34/100 overall, held back by a weak Value Compounder Score (20/100) indicating limited earnings power or capital efficiency, and moderate Leadership Alignment (45/100) suggesting misaligned incentives. Vulnerability Pro
0QOI.L's current Stocky Verdict is 34/100, placing it in the "Avoid" band. This composite combines a 20/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for NEWRON PHARMACEUTICALS SPA NEWR yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
NEWRON PHARMACEUTICALS SPA NEWR scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
NEWRON PHARMACEUTICALS SPA NEWR's Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to NEWRON PHARMACEUTICALS SPA NEWR.
Sign up free and unlock the full analysis on 0QOI.L — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 0QOI.L in the app.
